The Efficacy of 0.1% Tacrolimus Eye Drop for Noninfectious, Non-Necrotizing Anterior Scleritis

2019 ◽  
Author(s):  
Hiroyuki Yazu ◽  
Dai Miyazaki ◽  
Hiroshi Fujishima
Keyword(s):  
Intraocular Pressure ◽  
Standard Deviation ◽  
Adverse Events ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Steroid Treatment ◽  
Eye Drops ◽  
Topical Tacrolimus ◽  
Anterior Scleritis ◽  
Clinical Signs And Symptoms

Abstract BACKGROUND: To examine the efficacy of 0.1% tacrolimus eye drops in the treatment of noninfectious, non-necrotizing anterior scleritis. METHODS: This prospective, single-arm study included nine patients (4 males and 5 females; mean age = 59.4 years, standard deviation = 10.5) with anterior scleritis. All patients were first treated with steroids for 1 month and then switched to tacrolimus eye drops alone. We defined baseline as the initiation of steroid or tacrolimus eye drops. Hyperemia and pain were scored before each treatment, at 1 and 2 weeks, and at 1 month after initiation of each treatment by using 5 grades (0 = none; 1+ = mild; 2+ = moderate; 3+ = severe; 4+ = extremely severe). Intraocular pressure (IOP) was also measured from baseline to 6 months after initiating tacrolimus eye drops. Safety was assessed based on the severity and the incidence of adverse events. RESULTS: The scores of hyperemia and pain had significantly decreased from baseline by 1 week after initiating tacrolimus eye drops (both P < 0.05). No significant reduction was observed with steroid treatment throughout the 1-month period in terms of both scores. Tacrolimus eye drops elicited statistically significant differences in mean IOP over the course of treatment (P = 0.02). No additional medications were required to provide relief in any of the patients receiving tacrolimus treatment. No patient had infectious adverse events after initiation of tacrolimus treatment. CONCLUSIONS: Topical tacrolimus may effectively and immediately reduce clinical signs and symptoms of noninfectious, non-necrotizing anterior scleritis. TRIAL REGISTRATION: This trial was prospectively registered on 16/10/2015 under the number (UMIN000034460).

Efficacy and Safety of New Product of Recombinant Erythropoietin to Treat Cisplatin-Containing Regimens-Induced Moderate Anemia in Cancer Patients

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4583-4583
Author(s):  
Tubagus Djumhana Atmakusuma ◽  
Ary Harryanto Reksodiputro ◽  
Johan M Kurnianda
Keyword(s):  
Adverse Events ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Base Line ◽  
Recombinant Erythropoietin ◽  
Efficacy And Safety ◽  
Indonesian Population ◽  
Hematological Cancers ◽  
Moderate Anemia ◽  
Clinical Signs And Symptoms

Abstract Background: Exogenous erythropoietin (EPO) is used widespread to treat patients with chemotherapy-induced anemia. Most of EPO products available in market are quite expensive causing limitation of their use, especially in developing countries. Recently, a new and more economic product of rHu-EPO has been produced in China by recombinant genetic engineering using E.coli. A multi center (in Indonesia), pre- and post-study, open lable without control, has been performed to evaluate the efficacy and safety of this alternative product of rHu-EPO to treat cisplatin-induced anemia in Indonesian population. Methods: Thirty-seven patients with solid tumors and non-myeloid blood malignancies, receiving standard cisplatin-containing chemotherapy regimens were enrolled into this study. After chemotherapy, hemoglobin level of the patients were monitored since the first cycle of chemotherapy regimen.When moderate anemia (Hb 8 – 10 g/dl) was developed after chemotherapy (in any cycle of chemotherapy), the patient was enrolled into the study based on the inclusion and exclusion criteria. If the Hb level was &lt; 8 g/dl, the patient would receive blood transfusion until 8 g/dl. rHu –EPO was given three times a week, 150 IU/body weight (SC) during the subsequent two cycles of chemotherapy regimens until the Hb level &gt; 10 g/dl.The efficacy was assessed by the increasing of Hb level and hematocrit (Ht) from the base line until &gt; 10 g/dl or Ht &gt; 30 %. The safety was assessed by clinical signs and symptoms of adverse events. Results: Of 37 patients, only 14 patients could be assessed. The remaining patients were excluded from the study due to some reasons; in 13 patients due to the Hb levels have been kept &gt; 10 g%, 5 patients due to the positive stool Benzidine tests, 1 patient due to the positive Coombs test, and others. Of the analyzed 14 patients, 10 patients with solid tumor cancers and 4 patients with non myeloid hematological cancers, 10 males and 4 females, age ranged 17 – 72 years old, 10 patients received Cisplatin-5 FU regimens, 4 patients received Cisplatin plus other chemotherapies. Pre-EPO laboratory tests revealed the Hb levels ranged 8.83 – 9.45 g/dl, Ht 26.34 – 28.50 %, reticulocyte 1.48 – 2.42 %, MCV 81.92 – 91.48 fl,MCH 27.27 – 30.65 pg, ureum 21.75 – 30.33 mg/dl, creatinine 0.80 – 1.07 mg/dl, erythropoietin level 26.49 – 128.44 U/L, with negative Coombs tests and Benzidine tests. The dosage of rHu-EPO varied between 5,700 – 10,000 IU. The number of rHu-EPO given varied between 2 – 11 cycles. 2 patients received blood transfusions (each 2 units) prior to rHu-EPO. The efficacy of rHu-EPO was shown by statistical evaluation (paired t-test) comparing pre- and post-rHu-EPO, in which the Hb levels were significantly increased (p=0.000) as well as the Ht were significantly increased (p=0.014). The safety of the rHu- EPO was demonstrated by the minimum adverse events developed during the rHu-EPO administration which thought to be due to other drugs (e.g. chemotherapy) which were received concomitantly (fatigue 42.85 %, nausea & vomiting 35.71 %, anorexia 21.42 %, headache 14.28 %, stomatitis 14.28 %, fever 7.14 %, arthralgia 7.14 %, abdominal pain 7.14 %, cough 7.14 %, dysphagia 7.14 %). Conclusion: The administration of the more affordable rHu-EPO has significantly increased the Hb levels as well as the Ht with minimum adverse events;the adverse events were mostly due to other drugs concomitantly received by the patients in Indonesian population.

scholarly journals Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the first Alois Alzheimer’s Clinical Notes

Geriatrics ◽  
2021 ◽  
Vol 6 (1) ◽  
pp. 5
Author(s):  
Donatella Rita Petretto ◽  
Gian Pietro Carrogu ◽  
Luca Gaviano ◽  
Lorenzo Pili ◽  
Roberto Pili
Keyword(s):  
Young Woman ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Neurocognitive Disorders ◽  
Lessons Learned ◽  
Alzheimer Dementia ◽  
Clinical Notes ◽  
Alois Alzheimer ◽  
Clinical Signs And Symptoms

Over 100 years ago, Alois Alzheimer presented the clinical signs and symptoms of what has been later called “Alzheimer Dementia” in a young woman whose name was Augustine Deter [...]

scholarly journals Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome

Pituitary ◽  
2020 ◽  
Author(s):  
Eliza B. Geer ◽  
Roberto Salvatori ◽  
Atanaska Elenkova ◽  
Maria Fleseriu ◽  
Rosario Pivonello ◽  
...  
Keyword(s):  
Cushing’S Syndrome ◽  
Patient Reported Outcomes ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Cushing's Syndrome ◽  
Original Version ◽  
Patient Reported ◽  
Author Group ◽  
Clinical Signs And Symptoms

The original version of the article unfortunately contained an error in the first name and the surname of one of the authors in the author group. The last author name was incorrectly published as ‘F. Pecori Giraldi’ and the corrected name is ‘Francesca Pecori Giraldi’ (First name: Francesca; Surname: Pecori Giraldi).

scholarly journals A 38-year demographic study of central and peripheral giant cell granulomas of the jaws

2016 ◽  
Vol 15 (2) ◽  
pp. 220-223 ◽  
Author(s):  
Shadi Saghafi ◽  
Reza Zare-Mahmoodabadi ◽  
Narges Ghazi ◽  
Mohammad Zargari
Keyword(s):  
Giant Cell ◽  
Medical Science ◽  
Age Distribution ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Posterior Maxilla ◽  
Frequent Site ◽  
Male Patients ◽  
Clinical Signs And Symptoms ◽  
Anterior Mandible

Objective: The purpose of this study was to retrospectively analyze the demographic characteristics of patients with central giant cell granulomas (CGCGs) and peripheral giant cell granulomas (PGCGs) in Iranian population.Methods: The data were obtained from records of 1019 patients with CGCG and PGCG of the jaws referred to our department between 1972 and 2010. This 38-year retrospective study was based on existing data. Information regarding age distribution, gender, location of the lesion and clinical signs and symptoms was documented. Results: A total of 1019 patients were affected GCGLs including 435 CGCGs and 584 PGCGs during the study. The mean age was 28.91 ± 18.16. PGCGs and CGCGs had a peak of occurrence in the first and second decade of life respectively. A female predominance was shown in CGCG cases (57.70%), whereas PGCGs were more frequent in males (50.85%). Five hundred and ninety-eight cases of all giant cell lesions (58.7 %) occurred in the mandible. Posterior mandible was the most frequent site for both CGCG and PGCG cases. The second most common site for PGCG was posterior maxilla (21%), whereas anterior mandible was involved in CGCG (19.45%). The majority of patients were asymptomatic. Conclusions: In contrast to most of previous studies PGCGs occur more common in the first decade and also more frequently in male patients. Although the CGCGs share some histopathologic similarities with PGCGs, differences in demographic features may be observed in different populations which may help in the diagnosis and management of these lesions.Bangladesh Journal of Medical Science Vol.15(2) 2016 p.220-223

scholarly journals Is Bisphosphonate-Related Osteonecrosis of the Jaw an Infection? A Histological and Microbiological Ten-Year Summary

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
A. M. Hinson ◽  
C. W. Smith ◽  
E. R. Siegel ◽  
B. C. Stack
Keyword(s):  
Systematic Review ◽  
Disease Severity ◽  
Large Scale ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Osteonecrosis Of The Jaw ◽  
Multifactorial Disease ◽  
Clinical Signs And Symptoms ◽  
Surgical Treatments

The role of infection in the etiology of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is poorly understood. Large-scale epidemiological descriptions of the histology and microbiology of BRONJ are not found in the literature. Herein, we present a systematic review of BRONJ histology and microbiology (including demographics, immunocompromised associations, clinical signs and symptoms, disease severity, antibiotic and surgical treatments, and recovery status) validating that infection should still be considered a prime component in the multifactorial disease.

Phasic jaw motor episodes in healthy subjects with or without clinical signs and symptoms of sleep bruxism: a pilot study

2013 ◽  
Vol 18 (1) ◽  
pp. 187-193 ◽  
Author(s):  
Shuichiro Yoshizawa ◽  
Takeshi Suganuma ◽  
Masayuki Takaba ◽  
Yasuhiro Ono ◽  
Takuro Sakai ◽  
...  
Keyword(s):  
Pilot Study ◽  
Healthy Subjects ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Sleep Bruxism ◽  
Clinical Signs And Symptoms
Sign in / Sign up

Export Citation Format

Share Document